Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AMM:DADI'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -10.01 Med: 2.52 Max: 8.96
Current: 5.07
During the past 13 years, Dar Al Dawa Development and Investment's highest Return-on-Tangible-Asset was 8.96%. The lowest was -10.01%. And the median was 2.52%.
AMM:DADI's Return-on-Tangible-Asset is ranked better than 58.63% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.155
vs AMM:DADI: 5.07
Dar Al Dawa Development and Investment (AMM:DADI) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Dar Al Dawa Development and Investment Return-on-Tangible-Asset Related Terms
Dar Al Dawa Development and Investment Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment Return-on-Tangible-Asset Chart
Dar Al Dawa Development and Investment Annual Data
AMM:DADI vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dar Al Dawa Development and Investment Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dar Al Dawa Development and Investment's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Dar Al Dawa Development and Investment's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 1.81% mean?
Dar Al Dawa Development and Investment (AMM:DADI) has a Return-on-Tangible-Asset of 1.81% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Dar Al Dawa Development and Investment and its competitors. This is 28% below median its historical median of 2.52. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #417 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is Dar Al Dawa Development and Investment's Return-on-Tangible-Asset too high?
Dar Al Dawa Development and Investment's current Return-on-Tangible-Asset of 1.81% is 28% below median its 10-year median of 2.52. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Dar Al Dawa Development and Investment's value of 1.81% is 42.6% below this industry median. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #417 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #417 out of 1008 companies for Return-on-Tangible-Asset. This puts Dar Al Dawa Development and Investment in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.16. Dar Al Dawa Development and Investment's value of 1.81% is 42.6% below this benchmark. While the company's 10-year median is 2.52 vs. the industry median of 3.16, Dar Al Dawa Development and Investment has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dar Al Dawa Development and Investment's current Return-on-Tangible-Asset of 1.81% is 42.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current Return-on-Tangible-Asset is 1.81%, which is 28% below median its own 10-year median of 2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Fairly Valued. The stock's GF Value™ is JOD1.10, compared to a current price of JOD1.14 — trading 3.6% above its estimated fair value. The current Return-on-Tangible-Asset is 1.81%, which is 28% below median its 10-year median of 2.52 and 42.6% below the Drug Manufacturers industry median of 3.16. Dar Al Dawa Development and Investment's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current Return-on-Tangible-Asset is 1.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued.
The current stock price of JOD1.14 is trading 3.6% above its estimated GF Value™ of JOD1.10.
GuruFocus considers Dar Al Dawa Development and Investment to be Fairly Valued.
Key valuation signals for AMM:DADI:
Return-on-Tangible-Asset: 1.81% (28% below median its 10-year median of 2.52)
GF Value™: JOD1.10 vs. price of JOD1.14 (3.6% above fair value)
Industry Position: 42.6% below the Drug Manufacturers median (#417 of 1008)
No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dar Al Dawa Development and Investment Business Description
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
78GF Score
Get the complete analysis for AMM:DADI
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:DADI has been successfully added to your 
